Fig. 7
MRGs with genetic mutations and immunotherapy. (A) The oncoplot depicted gene mutation differences in HCC patients between MRGs-high and -low groups. (B) Differential expression of DTYMK, ABCB6, GOT2 and TOMM40L between TP53-mut and -wt groups. (C) The scatterplot demonstrated the correlation of MRGs with tumor stemness indicators, DNAss and RNAss. (D–F) Differences in TMB, MSI, and TIDE scores of HCC patients between MRGs-high and -low groups. (G,H) Kaplan–Meier curves demonstrated the difference in progression-free survival (PFS) of patients treated with nivolumab or ipilimumab between the MRGs-high and -low groups. (I,J) Kaplan–Meier curves demonstrated the difference in PFS of melanoma patients treated with anti-PD-1 or ACT between the MRGs-high and -low groups using the GSE91061 and GSE100797 cohort, respectively. **P < 0.01, ***P < 0.001.
